{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:29:11Z","timestamp":1794324551606,"version":"4.9.0"},"reference-count":93,"publisher":"ScopeMed","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.medarch.org\/\/?sec=licenseinfo"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.5455\/medarh.2019.73.72-75","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T11:52:17Z","timestamp":1554983537000},"source":"Crossref","is-referenced-by-count":11,"title":["Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease\u00a0"],"prefix":"10.5455","member":"3407","reference":[{"key":"ref1","unstructured":"1. AD, Zakeri R, Quint JK. Defining the relationship between COPD"},{"key":"ref2","unstructured":"and CVD: what are the implications for clinical practice?.\u00a0Ther Adv"},{"key":"ref3","unstructured":"Respir Dis. 2018; 12: 1753465817750524."},{"key":"ref4","unstructured":"2. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Co -"},{"key":"ref5","unstructured":"morbidities in chronic obstructive pulmonary disease.\u00a0Proc Am"},{"key":"ref6","unstructured":"Thorac Soc. 2008; 5(4): 549-555."},{"key":"ref7","unstructured":"3. Sessler CN,\u00a0Cohen MD. Cardiac arrhythmias during theophyl -"},{"key":"ref8","unstructured":"line toxicity. A prospective continuous electrocardiographic study."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Chest.\u00a01990 Sep; 98(3): 672-678.","DOI":"10.1378\/chest.98.3.672"},{"key":"ref10","unstructured":"4. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in"},{"key":"ref11","unstructured":"patients with chronic obstructive pulmonary disease and concom-"},{"key":"ref12","unstructured":"itant cardiovascular conditions.\u00a0Int J Chron Obstruct Pulmon Dis."},{"key":"ref13","unstructured":"2007; 2(4): 535-540."},{"key":"ref14","unstructured":"5. Heindl\u00a0 S, Lehnert\u00a0 M,\u00a0 Criee\u00a0 CP,\u00a0et al Marked sympathetic activa -"},{"key":"ref15","unstructured":"tion in patients with chronic respiratory . ailure.\u00a0Am J Respir Crit"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Care Med.\u00a02001;\u00a0164:\u00a0597-601.","DOI":"10.1164\/ajrccm.164.4.2007085"},{"key":"ref17","unstructured":"6. Huang YL, Lai CC, Wang YH, et al. Impact of selective and nonse -"},{"key":"ref18","unstructured":"lective beta-blockers on the risk of severe exacerbations in patients"},{"key":"ref19","unstructured":"with COPD.\u00a0Int J Chron Obstruct Pulmon Dis. 2017; 12: 2987-2996."},{"key":"ref20","unstructured":"7. Chang CL,\u00a0Mills GD,\u00a0McLachlan JD, et al. Cardio-selective and"},{"key":"ref21","unstructured":"non-selective beta-blockers in chronic obstructive pulmonary dis -"},{"key":"ref22","unstructured":"ease: effects on bronchodilator response and exercise. Intern Med"},{"key":"ref23","unstructured":"J.\u00a02010 Mar; 40(3): 193-200."},{"key":"ref24","unstructured":"8. Liao KM, Lin TY, Huang YB, Kuo CC, Chen CY. The evaluation of"},{"key":"ref25","unstructured":"\u03b2-adrenoceptor blocking agents in patients with COPD and conges -"},{"key":"ref26","unstructured":"tive heart failure: a nationwide study.\u00a0Int J Chron Obstruct Pulmon"},{"key":"ref27","unstructured":"Dis. 2017; 12: 2573-2581."},{"key":"ref28","unstructured":"9. Duffy S, Marron R, Voelker H, et al. Effect of beta-blockers on exac-"},{"key":"ref29","unstructured":"erbation rate and lung function in chronic obstructive pulmonary"},{"key":"ref30","unstructured":"disease (COPD).\u00a0Respir Res. 2017; 18(1): 124."},{"key":"ref31","unstructured":"10. Begic E, Mujakovic A, Hodzic E, et al. The safety of beta-blocker use"},{"key":"ref32","unstructured":"in chronic obstructive pulmonary disease. Abstract book, 8th Pul -"},{"key":"ref33","unstructured":"mology days, Tesanj, Bosnia and Herzegovina. 37-39."},{"key":"ref34","unstructured":"11. Smith SC, Allen J, Blair SN, et al. . AHA\/ACC Guidelines for Sec-"},{"key":"ref35","unstructured":"ondary Prevention for Patients With Coronary and Other Athero -"},{"key":"ref36","unstructured":"sclerotic Vascular Disease: 2006 Update Endorsed by the National Heart, Lung, and Blood Institute. Journal of the American College"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"of Cardiology, 2006; 47(10): 2130-2139.","DOI":"10.1016\/j.jacc.2006.04.026"},{"key":"ref38","unstructured":"12. Abraham WT, Chin FMH, Feldman AM, et al. 2009 Focused Up -"},{"key":"ref39","unstructured":"date Incorporated Into the ACC\/AHA 2005 Guidelines for the Di -"},{"key":"ref40","unstructured":"agnosis and Management of Heart Failure in Adults. Journal of the"},{"key":"ref41","unstructured":"American College of Cardiology, 2009;\u00a0 53(15): e1-90."},{"key":"ref42","unstructured":"13. Lim KP, Loughrey S, Musk M, et al. Beta-blocker under-use in COPD"},{"key":"ref43","unstructured":"patients.\u00a0Int J Chron Obstruct Pulmon Dis. 2017; 12: 3041-3046."},{"key":"ref44","unstructured":"14. Bhatt SP, Wells JM, Kinney GL, et al. \u03b2-Blockers are associated with"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"a reduction in COPD exacerbations.\u00a0Thorax. 2015; 71(1): 8-14.","DOI":"10.1136\/thoraxjnl-2015-207251"},{"key":"ref46","unstructured":"15. Du Q, Sun Y, Ding N, et al. Beta-blockers reduced the risk of mor -"},{"key":"ref47","unstructured":"tality and exacerbation in patients with COPD: a meta-analysis of"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"observational studies.\u00a0PLoS One. 2014; 9(11): e113048.","DOI":"10.1371\/journal.pone.0113048"},{"key":"ref49","unstructured":"16. Au DH, Bryson CL, Fan VS, Udris EM, Curtis JR, et al. \u00a0Beta-block -"},{"key":"ref50","unstructured":"ers as single-agent therapy for hypertension and the risk of mortal -"},{"key":"ref51","unstructured":"ity among patients with chronic obstructive pulmonary disease.\u00a0Am"},{"key":"ref52","unstructured":"J Med. 2004; 117: 925-931.."},{"key":"ref53","unstructured":"17. Schnell K,\u00a0Weiss CO,\u00a0Lee T, et\u00a0al.\u00a0The prevalence of clinically\u2010relevant"},{"key":"ref54","unstructured":"comorbid conditions in patients with physician\u2010diagnosed COPD: a"},{"key":"ref55","unstructured":"cross\u2010sectional study using data from NHANES 1999\u20132008.\u00a0BMC"},{"key":"ref56","unstructured":"Pulm Med.\u00a02012; 12: 26-34."},{"key":"ref57","unstructured":"18. Angeloni E,\u00a0Melina G,\u00a0Roscitano A, et\u00a0al.\u00a0\u03b2\u2010blockers improve sur -"},{"key":"ref58","unstructured":"vival of patients with chronic obstructive pulmonary disease after"},{"key":"ref59","unstructured":"coronary artery bypass grafting.\u00a0Ann Thorac Surg.\u00a02013; 95: 525-531."},{"key":"ref60","unstructured":"19. van Gestel YR,\u00a0Hoeks SE,\u00a0Sin DD, et\u00a0al.\u00a0Impact of cardioselective"},{"key":"ref61","unstructured":"\u03b2\u2010blockers on mortality in patients with chronic obstructive pul -"},{"key":"ref62","unstructured":"monary disease and atherosclerosis.\u00a0Am J Respir Crit Care Med."},{"key":"ref63","unstructured":"2008; 178: 695-700."},{"key":"ref64","unstructured":"20. Rutten FH,\u00a0Zuithoff PA,\u00a0Hak E, et\u00a0al.\u00a0\u03b2\u2010blockers may reduce mor -"},{"key":"ref65","unstructured":"tality and risk of exacerbations in patients with chronic obstructive"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"pulmonary disease.\u00a0Arch Intern Med.\u00a02010; 170: 880-887.","DOI":"10.1001\/archinternmed.2010.112"},{"key":"ref67","unstructured":"21. Farland MZ,\u00a0Peters CJ,\u00a0Williams JD, et\u00a0al.\u00a0Beta\u2010blocker use and inci -"},{"key":"ref68","unstructured":"dence of chronic obstructive pulmonary disease exacerbations.\u00a0Ann"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Pharmacother.2013; 47: 651-656.","DOI":"10.1345\/aph.1R600"},{"key":"ref70","unstructured":"22. Minor DS, Meyer AM, Long RC, et al. \u03b2\u2010Blockers and Chronic Ob -"},{"key":"ref71","unstructured":"structive Pulmonary Disease: Inappropriate Avoidance?. J Clin Hy -"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"pertens\u00a0(Greenwich).\u00a02013; 15: 925-930.","DOI":"10.1111\/plb.12075"},{"key":"ref73","unstructured":"23. Dargie H, Rowland E, Krikler D. Role of calcium antagonists in car -"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"diovascular therapy. Br Heart J. 1981; 46: 8-16.","DOI":"10.1136\/hrt.46.1.8"},{"key":"ref75","unstructured":"24. Jordaens L, Trouerbach J, Calle P, et al. Conversion of atrial fibrilla -"},{"key":"ref76","unstructured":"tion to sinus rhythm and rate control by digoxin in comparison to"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"placebo.\u00a0Eur Heart J.\u00a01997; 18: 643-648.","DOI":"10.1093\/oxfordjournals.eurheartj.a015310"},{"key":"ref78","unstructured":"25. Roberts SA, Diaz C, Nolan PE, et al. Effectiveness and costs of di -"},{"key":"ref79","unstructured":"goxin treatment for atrial fibrillation and flutter.\u00a0Am J Cardiol.\u00a01993;"},{"key":"ref80","unstructured":"72: 567-573."},{"key":"ref81","unstructured":"26. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update in-"},{"key":"ref82","unstructured":"corporated into the acc\/aha 2005 guidelines for the diagnosis and"},{"key":"ref83","unstructured":"management of heart failure in adults: A report of the American"},{"key":"ref84","unstructured":"college of cardiology foundation\/American heart association task"},{"key":"ref85","unstructured":"force on practice guidelines: Developed in collaboration with the"},{"key":"ref86","unstructured":"international society for heart and lung transplantation.\u00a0Circula -"},{"key":"ref87","unstructured":"tion.\u00a02009; 119: e391-e479.."},{"key":"ref88","unstructured":"27. Patel K, Fonarow GC, Ahmed M, et al. Calcium channel blockers and"},{"key":"ref89","unstructured":"outcomes in older patients with heart failure and preserved ejection"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"fraction.\u00a0Circ Heart Fail. 2014; 7(6): 945-952.","DOI":"10.1161\/CIRCHEARTFAILURE.114.001301"},{"key":"ref91","unstructured":"28. Ledwitch KV,\u00a0 Barnes RW,\u00a0 Roberts AG. Unraveling the complex"},{"key":"ref92","unstructured":"drug\u2013drug interactions of the cardiovascular drugs, verapamil and"},{"key":"ref93","unstructured":"digoxin, with P-glycoprotein. Bioscience Reports Apr 2016, 36(2):"}],"container-title":["Medical Archives"],"original-title":[],"link":[{"URL":"https:\/\/ejmanager.com\/mnstemps\/10\/10-1554627284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:56:19Z","timestamp":1791482179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejmanager.com\/mnstemps\/10\/10-1554627284.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":93,"URL":"https:\/\/doi.org\/10.5455\/medarh.2019.73.72-75","relation":{},"ISSN":["0350-199X"],"issn-type":[{"value":"0350-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}